BASIC AND CLINICAL STUDIES ON CEFCLIDIN FOR SURGICAL APPLICATION
-
- Yura Jiro
- The 1st. Department of Surgery, Nagoya City University, Medical School
-
- Shinagawa Nagao
- The 1st. Department of Surgery, Nagoya City University, Medical School
-
- Ishikawa Shu
- The 1st. Department of Surgery, Nagoya City University, Medical School
-
- Mizuno Akira
- The 1st. Department of Surgery, Nagoya City University, Medical School
-
- Mashita Keiji
- The 1st. Department of Surgery, Nagoya City University, Medical School
-
- Hori Keiichi
- The 1st. Department of Surgery, Nagoya City University, Medical School
-
- Suzui Katsuya
- The 1st. Department of Surgery, Nagoya City University, Medical School
-
- Sakurai Satoshi
- The 1st. Department of Surgery, Nagoya City University, Medical School
-
- Muramoto Masayuki
- The 1st. Department of Surgery, Nagoya City University, Medical School
-
- Nakamura Tsukasa
- The 1st. Department of Surgery, Nagoya City University, Medical School
-
- Ishihara Hiroshi
- The 1st. Department of Surgery, Nagoya City University, Medical School
Bibliographic Information
- Other Title
-
- 外科領域におけるcefclidinの基礎的・臨床的検討
Abstract
Basic and clinical studies on cefclidin (CFCL), a newly developed injectable cephem antibiotic, were carried out in the field of surgery, and the following results were obtained.<BR>1. Antibacterial activity MIC50/MIC90 (μg/ml) of CFCL against clinical isolates from surgical infections, of Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, were 12.5/100, 0.1/0.78., 0.1/0.39, and 3.13/12.5, respectively. Antibacterial activity of CFCL against S.aureus was as strong as those of ceftazidime (CAZ). However, the activity of CFCL against E.coli and K.pneumoniae, was equal or superior to activities of CAZ, and CFCL showed the most powerful activity against P.aeruginosa among all drugs tested.<BR>2. Penetration into bile and ascites: Biliary levels of CFCL were determined in 6 patients. The mean peak level of CFCL after the administration at 1 hour after dosing of 1g (i.v.) was 17.4μg/ml. No accumulation of CFCL was recognized in bile after the repeat administration. Meanwhile, the mean peak level of CFCL in ascites on for 5 patients reached 30.6μg/ml after the dosing of 1g (i.v.)<BR>3. Clinical results: CFCL was administered to 24 patients with surgical infections. The clinical responses were excellent in 3 cases, good in 11, fair in 6, poor in 3, unevaluable in 1 and the overall efficacy rate was 61%. Bacteriological responses were eradicated in 4 cases, partially eradicated in 4, persisted in 2, replaced in 5 and the overall eradicated rate was 60%.<BR>No adverse reaction was noted. Abnormal laboratory findings were recognized in 6 cases but these abnormal changes returned to normal ranges after the termination of dosing.
Journal
-
- CHEMOTHERAPY
-
CHEMOTHERAPY 40 (Supplement4), 522-530, 1992
Japanese Society of Chemotherapy
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282681262023936
-
- NII Article ID
- 130004197976
-
- ISSN
- 18845894
- 00093165
-
- Data Source
-
- JaLC
- CiNii Articles
-
- Abstract License Flag
- Disallowed